Lumenis Ltd., the world’s largest energy-based medical device company for ophthalmic, aesthetic and surgical applications and the inventor of intense pulsed light (IPL) technology, today announced that the FDA has granted De Novo authorization for Lumenis’ newest IPL device for improving signs of dry eye disease due to meibomian gland dysfunction (MGD).
Fundamental Help for Patients: A 6-Month Look at Implementing Optima IPL
After just 6 months with Optima IPL, Carly Rose, OD is seeing incredible patient results, an increased demand in dry eye services, and a fast ROI on her investment.
Preview of the New Digital Duet/Trio, the First Digital SLT+YAG
Steven Dell, MD and Derek Cunningham, OD get a hands-on look at the improved digital capabilities of the newly released Digital Duet/Trio.
Stop the Drops: How SLT and IPL Improve Ocular Health and Quality of Life
Steven Vold, MD turns to two in-office solutions from Lumenis to reduce his patients’ dependence on drops and give them back control of their daily life.
6 Tips for Implementing Optima IPL in Your OD Practice
Make dry eye treatment a central focus of your OD practice with these tips for success from Jaime L. King, OD.
Telemedicine for Triage: Life-saving Now and Efficient in the Future
Adapting to the new normal during the pandemic, Douglas K. Devries, OD used telemedicine to his advantage to triage his dry eye patients, avoiding gaps in essential care.
COVID-19 Pandemic: Tips for Staying Connected with Dry Eye Patients
When COVID-19 forced a global shutdown, Bridgitte Shen Lee, OD planned ahead and developed creative ways to continue to serve her dry eye patients remotely.
Dell et al. (2017): Prospective evaluation of intense pulsed light and meibomian gland expression efficacy on relieving signs and symptoms of dry eye disease due to meibomian gland dysfunction
In a prospective single arm study, Lumenis IPL with OPT™ combined with MGX reduced the number and severity of symptoms and signs of dry eye disease in subjects with moderate to severe MGD.